Aligos Therapeutics, Inc. (ALGS) Stock Price & Analysis
Aligos Therapeutics, Inc. (ALGS) fell 4.11% to USD 5.96 as of September 8, 2026 at 14:04 UTC, according to Nexqual real-time market data.
ALGS last closed at USD 5.96; the session ranged USD 5.63–6.25 on volume of 44,613 shares. Market capitalization is —, with a 52-week range of USD 3.98–13.69 (NCM). Source: Nexqual, September 8, 2026 at 14:04 UTC.
Key Statistics (as of September 8, 2026 at 14:04 UTC)
| Price | USD 5.96 |
|---|---|
| Change | ▼ 4.11% (down) |
| Previous Close | USD 5.96 |
| Open | USD 5.96 |
| Day Range | USD 5.63 – 6.25 |
| 52-Week Range | USD 3.98 – 13.69 |
| Volume | 44,613 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ALGS)
Nexqual's technical model rates ALGS "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of September 8, 2026 at 14:04 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.16 (neutral) |
| vs SMA50 | Above (USD 5.93) |
| MACD | 0.09 (positive) |
Earnings (ALGS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -2.62 |
| Revenue Estimate | $5.97M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.14 vs est -1.38 ▲ beat |
| 2026-03-31 | USD -2.21 vs est -2.37 ▲ beat |
| 2025-12-31 | USD -1.91 vs est -2.49 ▲ beat |
| 2025-09-30 | USD -3.04 vs est -2.01 ▼ miss |
Source: Nexqual, September 8, 2026 at 14:04 UTC.
Financials & Fundamentals (ALGS)
| Total Revenue | $31.52M |
|---|---|
| Revenue Growth (YoY) | +2778.50% |
| Gross Margin | -180.40% |
| Operating Margin | -6.80% |
| Profit Margin | -241.01% |
| ROE | -113.59% |
| Debt / Equity | 10.99 |
| Current Ratio | 2.19 |
| Total Cash | $30.38M |
| Total Debt | $3.50M |
| Free Cash Flow | $-61.39M |
Source: Nexqual, September 8, 2026 at 14:04 UTC.
Financial Health Score (ALGS)
Nexqual rates Aligos Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 14:04 UTC.
| Growth | Critical — Revenue -45% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $30M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$61M, burning cash |
| Efficiency | Critical — ROE -114%, ROA -49.1% |
Ownership (ALGS)
| Insider Ownership | +10.64% |
|---|---|
| Institutional Ownership | +45.65% |
| Shares Outstanding | 5.44M |
| Float | 3.70M |
| Short % of Float | +10.71% |
Source: Nexqual, September 8, 2026 at 14:04 UTC.
Leadership (ALGS)
Aligos Therapeutics, Inc. is led by Lawrence M. Blatt (age 63), CEO, President & Chairman of the Board, per Nexqual as of September 8, 2026 at 14:04 UTC.
| CEO, President & Chairman of the Board | Lawrence M. Blatt (age 63) |
|---|---|
| Executive VP, CFO & COO | Lesley Ann Calhoun (age 59) |
| Executive VP & Chief Scientific Officer | Julian A. Symons DPHIL (age 63) |
| Executive Vice President & Chief Development Officer | Sushmita M. Chanda DABT (age 58) |
| Vice President & Head of Chemistry Manufacturing Controls | Kieron Wesson |
Major Backers & Investors (ALGS)
Notable institutional backers of Aligos Therapeutics, Inc. include Deep Track Capital, Lp, Alyeska Investment Group, L.p., Sio Capital Management, LLC, according to Nexqual as of September 8, 2026 at 14:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 7.11% |
| Alyeska Investment Group, L.p. | 6.6% |
| Sio Capital Management, LLC | 5.24% |
| Marshall Wace LLP | 3.95% |
| Woodline Partners LP | 2.84% |
| Baker Bros. Advisors, LP | 1.33% |
| HHLR Advisors, LTD | 1.22% |
| Shaw D.E. & Co., Inc. | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.62% |
Source: Nexqual, September 8, 2026 at 14:04 UTC.
From Aligos Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
- Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
- The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus.
- The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANNX | Annexon, Inc. | USD 4.72 | ▼ 2.48% |
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.32 | ▲ 6.45% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.01 | ▼ 1.23% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.83 | ▼ 0.92% |
| PASG | Passage Bio, Inc. | USD 4.64 | ▼ 2.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 14:04 UTC. This page is informational and not investment advice.